Circulating RNAs in prostate cancer patients


Posted: 2021-10-17 19:00:00
Cancer Lett . 2021 Oct 14;S0304-3835(21)00521-8. doi: 10.1016/j.canlet.2021.10.011. Online ahead of print. Affiliations Expand Affiliations 1 Department of Cellular, Computational and Integrative Biology (CIBIO), University of Trento, Trento, Italy. 2 Department of Cellular, Computational and Integrative Biology (CIBIO), University of Trento, Trento, Italy. Electronic address: f.demichelis@unitn.it. Item in Clipboard Vera Mugoni et al. Cancer Lett. 2021. Show details Display options Display options Format Cancer Lett . 2021 Oct 14;S0304-3835(21)00521-8. doi: 10.1016/j.canlet.2021.10.011. Online ahead of print. Affiliations 1 Department of Cellular, Computational and Integrative Biology (CIBIO), University of Trento, Trento, Italy. 2 Department of Cellular, Computational and Integrative Biology (CIBIO), University of Trento, Trento, Italy. Electronic address: f.demichelis@unitn.it. Item in Clipboard CiteDisplay options Display options Format Abstract Growing bodies of evidence have demonstrated that the identification of prostate cancer (PCa) biomarkers in the patients' blood and urine may remarkably improve PCa diagnosis and progression monitoring. Among diverse cancer-derived circulating materials, extracellular RNA molecules (exRNAs) represent a compelling component to investigate cancer-related alterations. Once outside the intracellular environment, exRNAs circulate in biofluids either in association with protein complexes or encapsulated inside extracellular vesicles (EVs). Notably, EV-associated RNAs (EV-RNAs) were used for the development of several assays (such as the FDA-approved Progensa Prostate Cancer Antigen 3 (PCA3 test) aiming at improving early PCa detection. EV-RNAs encompass a mixture of species, including small non-coding RNAs (e.g. miRNA and circRNA), lncRNAs and mRNAs. Several methods have been proposed to isolate EVs and relevant RNAs, and to perform RNA-Seq studies to identify potential cancer biomarkers. However, EVs in the circulation of a cancer patient include a multitude of diverse populations that are released by both cancer and normal cells from different tissues, thereby leading to a heterogeneous EV-RNA-associated transcriptional signal. Decrypting the complexity of such a composite signal is nowadays the major challenge faced in the identification of specific tumor-associated RNAs. Multiple deconvolution algorithms have been proposed so far to infer the enrichment of cancer-specific signals from gene expression data. However, novel strategies for EVs sorting and sequencing of RNA associated to single EVs populations will remarkably facilitate the identification of cancer-related molecules. Altogether, the studies summarized here demonstrate the high potential of using EV-RNA biomarkers in PCa and highlight the urgent need of improving technologies and computational approaches to characterize specific EVs populations and their relevant RNA cargo. Keywords: Biomarkers; Computational biology; EV-RNA; Liquid biopsy; Prostate cancer; Transcriptomics; exRNA. Copyright © 2021. Published by Elsevier B.V. Conflict of interest statement Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. [x] Cite Copy Format: Send To [x]

参考サイト PubMed: exsome


Powered by Kreditvergleich


バイオクイックニュース日本語版:エクソソーム特集

バイオクイックニュース日本語版
8月 19, 2020 バイオアソシエイツ

ISEV2020バーチャル年次総会の注目の要旨に、Ral-GTPaseがどのようにエクソソームの生合成と臓器向性を制御し転移を促進するかに焦点を当てた発表が選ばれた。

7月20〜22日に開催されたISEV2020仮想年次総会(International Society for Extracellular Vesicles)で、フランス・ストラスブール大学のJacky Goetz博士の腫瘍メカニクスラボに所属するShima Ghoroghi氏(写真)は、「Ral-GTPaseは、 エクソソーム の生合成と臓器向性を制御することにより転移を促進する(Ral-GTPases Promote Metastasis by Controlling Biogenesis and…

ゲスト 587人 と メンバー 6人 がオンラインです